Comparing Growth Prospects: Surrozen vs. Tenaya Therapeutics Surrozen and Tenaya Therapeutics, both in the biotech space, show contrasting profiles. Tenaya boasts higher institutional ownership and a significant upside potential of over 3,700%, compared to Surrozen’s 222%. However, both firms face challenges, including negative earnings and profitability metrics, underscoring the risks in this sector.2